KA Imaging Reports: Study Demonstrates Reveal 35C’s Impact in the ICU: Enhanced Imaging, Faster Diagnosis, and Potential CT Diversion

Better image quality, same reading times or faster, increased confidence in diagnosis, reduced time to potential intervention, and potential to divert cases from CT imaging. This is a summary of a study using the Reveal 35C detector in the ICU, to be presented at this year’s American Society of Emergency Radiology Meeting reports KA Imaging.

Quoting directly from the study: “In certain cases, especially when computed tomography (CT) is not an option, dual-energy X-ray can permit improved visualization of soft tissues by subtracting unwanted structural noise […] and simultaneously reducing unnecessary radiation exposure. Medical lines and tubes can be better visualized using the bone image that dual-energy X-ray detectors also produce.”

Radiologist Vikram Venkatesh, one of the study’s authors, explained the difficulties of imaging in the ICU: “In addition to their critical condition requiring intensive care, ICU patients often have multiple lines, tubes, and implantable devices, making it challenging to transport them to the medical imaging department.”

The study at Grand River Hospital (GRH), a 665-bed community hospital, focused on how the Reveal 35C detector could address these challenges by providing dual-energy images directly at the bedside. Seventeen respondents were interviewed, including radiologists and intensivists.

Results were positive for more than half of the physicians in all areas, with reported better image quality, no added or faster reading times, increased confidence in diagnosis, and a reduction in time to potential intervention.

Another outcome observed was the potential for CT diversion. In addition to the self-reported reduction trend noted by intensivists, data collected at the hospital showed a decrease in the number of chest CTs during the study period compared to other time frames: a 37.5% decrease compared to the prior 3 months and a 16.67% decline compared to the identical period in the previous year.

In the ICU, due to the capitated nature of reimbursement, hospitals are encouraged to manage costs effectively. “Along with the cost savings from each avoided CT scan, there are further benefits like avoiding re-intubation, reducing transport risks, and improving infection control,” analyzed Amol Karnick, president and CEO of KA Imaging.

The American Society of Emergency Radiology (ASER) Meeting will be held from September 11 to 14 in Washington, DC. In addition to the poster session, visitors can learn about KA Imaging’s technology at the technical exhibition.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version